Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Standard Specimen Reference Set: Liver

Standard Specimen Reference Set: Liver

134
Parikh, NeeharUniversity of Michigan

No involved investigator sites defined.

N/A
Other, Specify
G.I. and Other Associated Cancers Research Group

Utilize the remaining specimens collected under the DCP protocol to develop and validate markers for the early detection of HCC

Specific Aims Aim 1: To determine the sensitivity and specificity of des-gamma carboxyprothrombin (DCP) for the diagnosis of early hepatocellular carcinoma (HCC). Aim 2: To compare the accuracy of DCP and Alpha-fetoprotein (AFP) for the diagnosis of early HCC. Aim 3: To determine whether demographic or etiology of underlying liver disease alter the expression of DCP or AFP.
N/A

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.